OCD Pharmacotherapy: SSRIs, Clomipramine, and Augmentation Strategies — Mechanisms, Outcome Data, and Clinical Decision-Making

Obsessive-compulsive disorder (OCD) is a chronic, often debilitating psychiatric condition characterized by recurrent, intrusive thoughts (obsessions) and repetitive behaviors or mental acts (compulsions) performed to reduce associated distress. The DSM-5-TR classifies OCD within its own diagnostic category — Obsessive-Compulsive and Related Disorders — reflecting its distinct neurobiological profile and treatment response patterns that differentiate it from anxiety disorders proper.

Pharmacotherapy remains a cornerstone of OCD management, yet the treatment landscape is considerably narrower than for major depressive disorder or generalized anxiety. Serotonin reuptake inhibitors (SRIs) — including selective serotonin reuptake inhibitors (SSRIs) and the tricyclic antidepressant clomipramine — constitute the only FDA-approved first-line pharmacological agents. This narrow pharmacological window itself provides critical neurobiological insight: OCD is one of the few psychiatric conditions where potent serotonergic blockade is both necessary and, in many cases, insufficient.

Approximately 40–60% of patients show a meaningful response to first-line SRI monotherapy, and full remission is achieved in only 20–30% of cases. This leaves a substantial treatment gap that has driven intensive research into augmentation strategies, novel mechanisms, and combination approaches. This article provides a comprehensive review of the evidence base for OCD pharmacotherapy, including specific outcome data, comparative effectiveness, neurobiological rationale, and emerging frontiers.

OCD affects approximately 2–3% of the global population over the lifetime, with 12-month prevalence estimates of 1.0–1.2% in the United States according to the National Comorbidity Survey Replication (NCS-R) and NIMH data. The World Health Organization has ranked OCD among the top 10 most disabling illnesses globally in terms of lost income and diminished quality of life. The mean age of onset is bimodal, with an early-onset peak around age 10–12 (more common in males) and a later peak around age 20–22 (more evenly distributed by sex). Overall, the sex ratio in adults is roughly equal, though males tend to have earlier onset and higher rates of comorbid tic disorders.

The disorder follows a chronic waxing-and-waning course in most individuals. Epidemiological studies indicate that without treatment, spontaneous remission is rare — the Epidemiological Catchment Area (ECA) study and subsequent longitudinal research suggest that fewer than 20% of untreated patients achieve sustained remission over a decade. Mean time from symptom onset to first treatment contact is alarmingly long, estimated at 7–10 years, driven by shame, poor recognition, and the ego-dystonic nature of symptoms that paradoxically leads patients to conceal rather than report them.

The economic burden is substantial. Patients with OCD have significantly higher healthcare utilization, elevated rates of unemployment (estimated at 30–40% in moderate-to-severe cases), and marked occupational impairment. These statistics underscore the urgency of effective pharmacotherapy and the clinical significance of even partial treatment response.

The serotonin hypothesis of OCD is among the most robust pharmacological dissections in psychiatry. Unlike depression — where noradrenergic, serotonergic, and dopaminergic agents all demonstrate efficacy — OCD responds specifically and selectively to agents that potently inhibit the serotonin transporter (SERT). This was first demonstrated in the landmark finding that clomipramine, but not the structurally similar tricyclic desipramine (a predominantly noradrenergic reuptake inhibitor), was effective in OCD. This serotonergic selectivity has been replicated across dozens of trials and remains a defining pharmacological feature of the disorder.

The Cortico-Striato-Thalamo-Cortical (CSTC) Circuit

The prevailing neuroanatomical model implicates dysfunction in the cortico-striato-thalamo-cortical (CSTC) circuit, involving hyperactivity in the orbitofrontal cortex (OFC), anterior cingulate cortex (ACC), caudate nucleus, and thalamus. Neuroimaging studies consistently show elevated metabolic activity in the OFC and caudate at rest, which normalizes with successful treatment — whether pharmacological or behavioral. The Baxter et al. (1992) PET studies were among the first to demonstrate that both fluoxetine and ERP produced overlapping patterns of metabolic normalization in the caudate, a landmark convergence of biological and psychological treatment effects.

Serotonergic projections from the dorsal raphe nuclei densely innervate the OFC and striatum. The 5-HT2A and 5-HT1B receptor subtypes in orbitofrontal and striatal regions are particularly implicated. SRIs are hypothesized to reduce obsessional drive by desensitizing postsynaptic 5-HT2A receptors in the OFC and enhancing 5-HT1B-mediated inhibitory tone in the basal ganglia, effectively dampening the hyperactive direct pathway of the CSTC loop.

Beyond Serotonin: Glutamate and Dopamine

The limitations of the pure serotonin model are evident in the substantial non-response rate to SRIs. The glutamate hypothesis has gained significant traction: elevated cerebrospinal fluid glutamate levels have been found in OCD patients, and the CSTC circuit relies heavily on glutamatergic corticostriatal projections. Genetic studies have implicated variants in the SLC1A1 gene (encoding the neuronal glutamate transporter EAAT3), particularly in early-onset OCD. This has motivated trials of glutamate-modulating agents such as memantine, riluzole, and N-acetylcysteine as augmentation strategies.

Dopaminergic involvement is supported by the efficacy of low-dose antipsychotic augmentation (discussed below) and by the overlap between OCD and tic disorders. A subgroup of OCD patients — particularly those with comorbid tics, poor insight, symmetry/ordering symptoms, or early onset — may have greater dopaminergic dysfunction in the striatum. The D2 receptor system in the ventral striatum and the balance between direct (D1-mediated) and indirect (D2-mediated) basal ganglia pathways are central to this model.

Genetic Factors

OCD has a significant heritable component, with twin studies estimating heritability at 40–50% in adults and up to 65% in childhood-onset cases. Genome-wide association studies (GWAS), including the International OCD Foundation Genetics Collaborative (IOCDF-GC) studies, have identified suggestive loci but no single gene of large effect. Candidate gene studies have repeatedly implicated polymorphisms in SLC6A4 (serotonin transporter), HTR2A (5-HT2A receptor), SLC1A1 (glutamate transporter), and COMT (catechol-O-methyltransferase). The polygenic architecture explains why pharmacogenomic prediction of SRI response remains limited in clinical practice, though CYP2D6 and CYP2C19 genotyping can guide dosing decisions for specific SSRIs.

Five SSRIs have demonstrated efficacy in OCD through randomized controlled trials, and several are FDA-approved for this indication: fluoxetine, fluvoxamine, paroxetine, sertraline, and (though not FDA-approved specifically for OCD in all markets) citalopram and escitalopram, which have substantial RCT support. A critical clinical distinction from SSRI use in depression is that OCD typically requires higher doses and longer trial durations.

Dosing Considerations

The APA Practice Guidelines and expert consensus recommend the following target doses for OCD, which are often at or above the maximum doses used for depression:

• Fluoxetine: 40–80 mg/day
• Fluvoxamine: 200–300 mg/day
• Sertraline: 150–200 mg/day (some guidelines extend to 250 mg/day for OCD)
• Paroxetine: 40–60 mg/day
• Escitalopram: 20–40 mg/day (doses above 20 mg are off-label but supported by RCTs)

A fundamental clinical principle is that adequate trial duration for OCD is 8–12 weeks at maximum tolerated dose. This is substantially longer than the 4–6 weeks typically allowed for depression, reflecting the slower onset of anti-obsessional effect. The initial response may not emerge until week 4–6, and continued improvement can accrue through week 12 and beyond. Premature switching is a common clinical error.

Outcome Data

A pivotal Cochrane meta-analysis by Soomro et al. (2008), incorporating 17 RCTs with over 3000 participants, established that SSRIs are significantly superior to placebo for OCD, with a pooled standardized mean difference (SMD) of approximately −0.91 on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), representing a large effect size. However, the clinical picture is more nuanced:

• Response rates (typically defined as ≥25–35% reduction on Y-BOCS): approximately 40–60% with SSRIs vs. 10–20% with placebo
• Remission rates (Y-BOCS ≤ 12 or ≤ 14): approximately 20–30% with SSRI monotherapy
• Number needed to treat (NNT): estimated at 5–8 for response vs. placebo across meta-analyses
• Mean Y-BOCS reduction with SSRIs is typically 4–7 points greater than placebo, translating to a shift from severe to moderate symptom severity in responders

The SSRI dose-response relationship was examined in a meta-analysis by Bloch et al. (2010), which confirmed a significant dose-response effect: higher SSRI doses produced greater Y-BOCS reductions. This supports the clinical practice of dose escalation to maximum tolerated levels before concluding non-response.

Comparative SSRI Effectiveness

Head-to-head trials between SSRIs in OCD are limited. No single SSRI has consistently demonstrated superiority over another. The largest comparative data come from network meta-analyses, which suggest roughly equivalent efficacy across SSRIs, with individual patient tolerability and pharmacokinetic profiles guiding selection. Escitalopram has emerged in several recent meta-analyses as potentially having a slightly more favorable tolerability profile with comparable efficacy, but the magnitude of any difference is small. Fluvoxamine, among the earliest SSRIs studied in OCD, has robust efficacy data but is less commonly prescribed due to its twice-daily dosing, CYP inhibition profile (particularly CYP1A2 and CYP2C19), and somewhat higher drug-interaction burden.

Clomipramine, a tricyclic antidepressant (TCA) with potent serotonin reuptake inhibition as its primary mechanism, was the first agent demonstrated to be effective for OCD and remains arguably the most efficacious single pharmacological agent for the disorder. Its active metabolite, desmethylclomipramine, is a potent norepinephrine reuptake inhibitor, giving the parent compound a dual-action profile — though the anti-obsessional effect is attributed primarily to serotonergic activity.

Evidence of Superior Efficacy

Multiple meta-analyses, including the influential Greist et al. (1995) pooled analysis and subsequent Cochrane reviews, have suggested that clomipramine has a larger effect size than SSRIs for OCD. The SMD for clomipramine vs. placebo has been estimated at approximately −1.31, compared to approximately −0.91 for SSRIs as a class. However, this apparent superiority is controversial and likely inflated by several methodological factors:

• Earlier clomipramine trials used less rigorous methodology and less effective blinding (side effects of TCAs are more noticeable)
• Direct head-to-head comparisons between clomipramine and SSRIs (e.g., the Mundo et al. 2001 comparison of clomipramine vs. fluvoxamine, and the Bisserbe et al. 1997 trial of clomipramine vs. sertraline) generally show comparable efficacy
• When methodology and blinding quality are controlled for, the superiority of clomipramine is substantially diminished

Nevertheless, many clinicians regard clomipramine as the most potent SRI for OCD, and expert consensus guidelines (including the APA and NICE guidelines) recommend it as a second-line agent after SSRI failure — not because of inferior efficacy, but because of inferior tolerability.

Dosing and Tolerability

The target dose for clomipramine in OCD is 150–250 mg/day, with a maximum recommended dose of 250 mg/day. The side effect profile is substantially heavier than SSRIs and includes:

• Anticholinergic effects: dry mouth, constipation, urinary retention, blurred vision
• Cardiovascular effects: orthostatic hypotension, QTc prolongation, tachycardia (ECG monitoring recommended)
• Weight gain (often significant)
• Sedation
• Sexual dysfunction (comparable to SSRIs)
• Seizure risk: dose-dependent, approximately 1–2% at doses above 250 mg/day
• Lethality in overdose: a critical safety consideration vs. SSRIs

These tolerability limitations explain why SSRIs are preferred as first-line despite clomipramine's potentially equivalent or marginally superior efficacy. In clinical practice, clomipramine is most commonly used after failure of 2–3 adequate SSRI trials, or as augmentation added at low doses (25–75 mg/day) to an SSRI — a strategy that exploits the different pharmacological profiles but requires careful monitoring for serotonin syndrome and cardiac effects.

Given that 40–60% of patients do not respond adequately to SRI monotherapy, augmentation is a critical clinical strategy. The evidence base is most robust for antipsychotic augmentation, with emerging data for glutamate modulators and other novel agents.

Antipsychotic Augmentation

Low-dose atypical antipsychotic augmentation of SRIs is the most extensively studied augmentation strategy in OCD. The rationale derives from the dopaminergic hypothesis and the clinical observation that OCD with comorbid tics responds preferentially to this approach. Key evidence includes:

The Bloch et al. (2006) meta-analysis of double-blind, placebo-controlled antipsychotic augmentation trials — a landmark synthesis — found that approximately one-third (33%) of SRI-refractory patients responded to antipsychotic augmentation versus approximately 11% with placebo augmentation, yielding an NNT of approximately 4.5. The agents with the strongest evidence include:

• Risperidone (0.5–3 mg/day): The most studied agent, with multiple positive RCTs. Effect sizes are moderate. The McDougle et al. (2000) trial was among the first to demonstrate significant benefit. A meta-analysis of risperidone augmentation trials shows response rates of approximately 40–50% in SRI non-responders.
• Aripiprazole (5–15 mg/day): Has gained favor due to its partial D2 agonist profile and relatively favorable metabolic side-effect profile. Multiple RCTs show efficacy, with some meta-analyses suggesting comparable or even superior effectiveness to risperidone with better tolerability.
• Haloperidol (1–4 mg/day): The original agent studied for augmentation, particularly effective in the tic-related OCD subgroup. The McDougle et al. (1994) trial showed a 65% response rate in OCD patients with comorbid tics versus 0% for placebo — one of the most dramatic augmentation effects in the literature.
• Quetiapine (150–450 mg/day): Evidence is mixed. While some individual RCTs are positive, a meta-analysis by Denys et al. (2004) and subsequent analyses suggest less consistent benefit compared to risperidone or aripiprazole.
• Olanzapine (2.5–10 mg/day): Some positive RCT data, but metabolic side effects (weight gain, glucose dysregulation) limit its clinical utility as a first-choice augmentation agent.

Clinical predictors of antipsychotic augmentation response include the presence of comorbid tic disorders, poor insight, symmetry/ordering symptom dimensions, and early onset of OCD. Patients without these features have lower response rates to this strategy.

Important caveats: long-term safety of antipsychotic augmentation in OCD is a significant concern. Metabolic syndrome, tardive dyskinesia (even with atypicals, though at lower rates), and prolactin elevation are ongoing risks that must be weighed against benefit. Duration of augmentation trials should be at least 4–6 weeks before concluding non-response.

Glutamate-Modulating Agents

Given the glutamatergic hypothesis of OCD, several agents have been investigated:

• Memantine (5–20 mg/day): An NMDA receptor antagonist with the most encouraging augmentation data among glutamatergic agents. A Ghaleiha et al. (2013) RCT demonstrated significant Y-BOCS reduction with memantine augmentation of fluvoxamine. Subsequent meta-analyses of small trials suggest a moderate effect size, but larger confirmatory studies are needed.
• N-acetylcysteine (NAC, 2400–3000 mg/day): A glutamate modulator acting via the cystine-glutamate antiporter. A Afshar et al. (2012) double-blind RCT showed significant benefit as SRI augmentation, but replication has been inconsistent. Effect sizes are generally small to moderate.
• Riluzole (50–100 mg/day): A glutamate release inhibitor approved for ALS. Open-label and small controlled trials showed promise, but the Pittenger et al. (2015) larger controlled trial was negative for the primary outcome, tempering enthusiasm.

Other Augmentation Approaches

• Cognitive-behavioral therapy (CBT) augmentation: Adding exposure and response prevention (ERP) to SRI pharmacotherapy is the most robustly supported combination strategy. The Foa et al. (2005) landmark trial demonstrated that combined clomipramine + ERP was superior to either alone, and subsequent studies confirm that ERP augmentation produces incremental benefit over SRI monotherapy, with NNTs of approximately 3–4 for the addition of ERP to SRI.
• Lithium and buspirone augmentation: Despite initial case series enthusiasm, controlled trials have not supported efficacy for either agent in SRI-refractory OCD.
• Clomipramine + SSRI combination: Used in practice but without robust RCT support. Monitoring for pharmacokinetic interactions (SSRIs inhibit clomipramine metabolism, raising desmethylclomipramine levels) and serotonin syndrome is essential.

Based on synthesis of meta-analytic evidence, clinical guidelines (APA, NICE, CANMAT), and expert consensus, a rational stepped pharmacotherapy algorithm for OCD is as follows:

Step 1: SSRI Monotherapy

Begin with any SSRI at standard dose, titrate to maximum tolerated dose within 4–6 weeks, and allow 8–12 weeks of adequate-dose exposure before evaluating response. Concurrent initiation of CBT/ERP is recommended whenever accessible.

Step 2: Switch SSRI or Optimize Dose

For non-response to the first SSRI trial, switch to a different SSRI. Evidence suggests that approximately 25–30% of patients who fail one SSRI will respond to another. Alternatively, consider high-dose SSRI strategies (e.g., escitalopram 30–40 mg/day, sertraline 250 mg/day), which have emerging RCT support though are off-label in most jurisdictions.

Step 3: Clomipramine Trial

After failure of 2–3 SSRI trials, initiate clomipramine monotherapy at 25 mg/day and titrate to 150–250 mg/day. ECG monitoring at baseline and after dose stabilization is recommended. Some clinicians move to clomipramine earlier in the algorithm based on symptom severity and patient preference.

Step 4: Antipsychotic Augmentation

For SRI-refractory patients, add low-dose risperidone (0.5–2 mg/day) or aripiprazole (5–15 mg/day) as first-choice augmentation agents. If comorbid tics are present, antipsychotic augmentation may be prioritized earlier. Allow 4–6 weeks for assessment.

Step 5: Novel Augmentation / Combination Strategies

Consider memantine augmentation, combined SSRI + clomipramine (with monitoring), or referral for neurostimulation approaches (rTMS, deep brain stimulation for the most refractory cases). Ensure ERP has been attempted with adequate intensity.

Step 6: Treatment-Refractory Considerations

For patients who have failed multiple adequate trials across the algorithm, the classification of treatment-refractory OCD (typically defined as failure of ≥ 2 adequate SRI trials plus ≥ 1 augmentation trial plus adequate ERP) applies. Referral to specialized OCD treatment centers, consideration of intravenous clomipramine (available in some settings), or neuromodulation protocols may be warranted.

OCD rarely exists in isolation. Comorbidity profoundly influences treatment selection, expected outcomes, and prognosis. Key comorbidity patterns include:

Major Depressive Disorder (MDD)

The most common comorbidity, with lifetime prevalence of 63–67% in OCD populations (NCS-R data). Comorbid depression generally worsens OCD outcomes and is associated with higher Y-BOCS scores, greater functional impairment, and higher suicidality. The presence of depression does not fundamentally alter SSRI selection (SSRIs treat both conditions), but more severe depression may favor earlier use of clomipramine or consideration of adjunctive strategies targeting mood.

Anxiety Disorders

Generalized anxiety disorder (30%), social anxiety disorder (25%), and specific phobias (22%) commonly co-occur. These comorbidities generally respond to the same SRI pharmacotherapy, though dose optimization may need to account for multiple symptom domains.

Tic Disorders and Tourette Syndrome

Comorbid tic disorders are present in approximately 20–30% of OCD patients, with higher rates in males and early-onset cases. This subgroup shows preferential response to antipsychotic augmentation (particularly haloperidol and risperidone) as discussed above, and may represent a neurobiologically distinct subtype with greater striatal dopaminergic involvement.

OCD-Related Disorders

Body dysmorphic disorder (BDD), hoarding disorder, trichotillomania, and excoriation disorder share phenomenological and genetic overlap with OCD. BDD responds to SRIs with similar doses and timelines as OCD. Hoarding disorder, however, shows notably poorer response to SRI monotherapy, with response rates approximately 30% lower than for other OCD symptom dimensions.

Bipolar Disorder

OCD co-occurs with bipolar disorder in approximately 10–20% of cases. This comorbidity presents a pharmacological challenge, as SSRI and clomipramine use carries a risk of mood destabilization (mania/hypomania). Mood stabilizer co-administration is generally required, and careful risk-benefit analysis is essential.

Autism Spectrum Disorder (ASD)

Repetitive behaviors in ASD can mimic OCD, but pharmacological response in ASD-comorbid OCD is generally poorer. SRI response rates in this population are estimated at 30–40%, lower than the 40–60% in non-ASD OCD, and side-effect sensitivity (particularly behavioral activation) is higher.

Identifying predictors of pharmacotherapy response is critical for clinical decision-making and realistic expectation-setting. Research has identified several factors associated with better or worse outcomes:

Factors Associated with Better SRI Response

• Later onset of OCD (adult-onset vs. childhood-onset)
• Shorter duration of illness before treatment initiation
• Presence of contamination/washing symptoms (this dimension generally responds well to both SRIs and ERP)
• Good insight into the irrational nature of obsessions (DSM-5-TR specifies insight as a specifier: good/fair, poor, absent)
• Absence of comorbid personality disorders, particularly schizotypal personality disorder
• Absence of hoarding symptoms
• Concurrent ERP participation

Factors Associated with Poorer SRI Response

• Early onset (particularly before age 10)
• Comorbid tic disorders (though these patients may respond to augmentation)
• Hoarding symptoms as the predominant presentation
• Poor or absent insight — patients with overvalued ideation or delusional conviction about their obsessions show markedly reduced SRI response rates, estimated at < 25%
• Comorbid schizotypal personality disorder — the McDougle et al. (1993) study found that schizotypal comorbidity was a strong negative predictor of SRI response, with response rates near zero in this subgroup
• Family history of OCD — paradoxically associated with poorer pharmacotherapy outcomes in some studies, potentially reflecting a more genetically loaded variant
• Sexual/religious obsession dimension — mixed evidence, but some studies associate this dimension with slower or poorer SRI response

Long-Term Outcome Data

Long-term naturalistic follow-up studies provide a sobering perspective. The Skoog and Skoog (1999) 40-year prospective study of OCD patients found that approximately 20% achieved full remission, 28% had subclinical symptoms, and 48% continued to meet full diagnostic criteria decades later — though many of these patients predated modern pharmacotherapy. More recent long-term studies with treatment suggest that with sustained SRI pharmacotherapy, approximately 50–60% of initial responders maintain gains over 1–2 years, but relapse rates after SRI discontinuation are high — estimated at 24–89% depending on the study, with most estimates around 50–60% relapse within 2–3 months of discontinuation. This high relapse rate supports the recommendation for long-term or indefinite SRI maintenance in OCD, in contrast to the time-limited pharmacotherapy sometimes recommended for depression.

Accurate diagnosis is prerequisite to effective pharmacotherapy, and OCD presents several diagnostic challenges that can lead to misidentification and inappropriate treatment.

OCD vs. Generalized Anxiety Disorder (GAD)

Both conditions involve excessive worry. The distinction lies in content and form: OCD obsessions are typically ego-dystonic, intrusive, and thematically specific (contamination, harm, symmetry), while GAD worry is ego-syntonic, future-oriented, and spans multiple real-life domains. This distinction matters pharmacologically because while both conditions respond to SSRIs, the dose requirements and augmentation strategies differ.

OCD vs. Obsessive-Compulsive Personality Disorder (OCPD)

Despite the shared name, OCD and OCPD are distinct conditions. OCPD involves ego-syntonic perfectionism, rigidity, and control without true obsessions or compulsions. They can co-occur (approximately 25–30% overlap), but OCPD does not respond to SRI pharmacotherapy, and its presence may complicate OCD treatment by reducing insight and therapy engagement.

OCD vs. Psychotic Disorders

Approximately 4% of OCD patients have absent insight (delusional conviction), per DSM-5-TR, which can be misdiagnosed as a psychotic disorder. The DSM-5-TR insight specifier is critical here. Obsessional content involving harm, contamination, or bizarre themes can mimic delusions, but the repetitive, stereotyped nature and the presence of compulsions typically distinguish OCD. Importantly, antipsychotic monotherapy is ineffective for OCD and may worsen obsessions through 5-HT2A antagonism-related mechanisms — making accurate diagnosis essential.

OCD and PANDAS/PANS

Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and the broader Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) represent an abrupt-onset phenotype of OCD potentially triggered by infection-mediated autoimmune processes targeting the basal ganglia. While standard SRI pharmacotherapy is used for symptom management, additional immunomodulatory interventions may be warranted in confirmed cases. This remains an area of active clinical debate.

Several promising avenues are under investigation for OCD pharmacotherapy, driven by the inadequacy of current options for the large proportion of treatment-refractory patients.

Ketamine and NMDA Modulators

Building on ketamine's rapid antidepressant effects, early-phase studies have examined intravenous ketamine for OCD. The Rodriguez et al. (2013) randomized crossover trial found that a single ketamine infusion (0.5 mg/kg) produced rapid but transient anti-obsessional effects in treatment-refractory patients, with significant Y-BOCS reductions within hours that persisted for approximately one week. Replication has been inconsistent, and the durability of effects remains a major limitation. Intranasal esketamine is being explored but lacks published OCD-specific RCTs at this time.

Psilocybin and Serotonergic Psychedelics

Psilocybin, a 5-HT2A agonist, has generated interest based on case series and small open-label studies reporting acute and sustained reduction in OCD symptoms. The neurobiological rationale involves disruption of the hyperactive default mode network and CSTC circuits through 5-HT2A-mediated cortical plasticity. Phase 2 trials are underway, and this represents one of the most watched emerging frontiers. However, the evidence base remains preliminary, and the paradox of 5-HT2A agonism (psilocybin) vs. 5-HT2A antagonism (antipsychotic augmentation) both showing potential benefit highlights the complexity of serotonergic signaling in OCD.

Troriluzole and Next-Generation Glutamate Modulators

Troriluzole (BHV-4157), a prodrug of riluzole with improved bioavailability, underwent Phase 2/3 testing for OCD. While initial results were encouraging, the Phase 3 trial did not meet its primary endpoint, though subgroup analyses suggested potential benefit in specific patient populations. This illustrates the challenge of translating glutamatergic mechanism hypotheses into clinical efficacy.

Neuromodulation

While not pharmacotherapy per se, neuromodulation approaches are increasingly integrated into the treatment algorithm:

• Deep brain stimulation (DBS) of the ventral capsule/ventral striatum or the subthalamic nucleus has received a Humanitarian Device Exemption from the FDA for severe, treatment-refractory OCD. Response rates of approximately 50–60% are reported in small case series, though these are open-label and selection-biased.
• Repetitive transcranial magnetic stimulation (rTMS) targeting the pre-supplementary motor area (pre-SMA) or OFC received FDA clearance for OCD in 2018 (using the BrainsWay deep TMS device). The Carmi et al. (2019) multicenter sham-controlled trial showed significant Y-BOCS improvement with high-frequency pre-SMA stimulation, with a response rate of approximately 38% vs. 11% sham.

Precision Medicine Approaches

Neuroimaging biomarkers, particularly OFC and caudate hypermetabolism on PET and resting-state functional connectivity patterns, show promise in predicting SRI response. Machine learning approaches integrating clinical, genetic, and neuroimaging features are in development but remain investigational. The goal of matching individual patients to optimal pharmacological strategies based on biomarker profiles represents the long-term aspiration of OCD pharmacotherapy research.

Despite decades of research, several critical limitations characterize the OCD pharmacotherapy evidence base:

• Short trial durations: Most RCTs are 8–16 weeks, providing limited insight into the long-term effectiveness, tolerability, and relapse prevention that are essential for a chronic condition.
• Heterogeneity of response definition: The field lacks consensus on what constitutes clinically meaningful response. A 25% Y-BOCS reduction (commonly used) may not translate to functional improvement. Movement toward remission-focused outcomes is needed.
• Publication bias: Meta-analyses consistently detect publication bias in the SSRI literature for OCD, which may inflate efficacy estimates.
• Underrepresentation: Clinical trial populations are disproportionately white, adult, and without severe comorbidity, limiting generalizability to real-world clinical populations.
• Augmentation trial limitations: Antipsychotic augmentation trials are generally small (N = 20–50), short (4–8 weeks), and may not adequately control for expectation effects.
• Mechanism vs. treatment gap: Despite significant advances in understanding CSTC circuit dysfunction, this neurobiological knowledge has not yet translated into novel first-line treatments. The field remains reliant on drugs developed for depression (SSRIs) and psychosis (antipsychotics) repurposed for OCD.
• Treatment-refractory definition inconsistency: No universally accepted criteria for treatment-refractory OCD exist, making comparison across augmentation and neuromodulation studies difficult.

Acknowledging these limitations is essential for clinicians interpreting the evidence and communicating realistic expectations to patients. Despite these gaps, the existing evidence provides a sufficiently robust framework for systematic, evidence-based pharmacotherapy that can meaningfully reduce suffering for the majority of OCD patients.